Background/Aims: β-catenin is an integral component of the canonical Wnt signaling pathway, and its mutations are an autosomal recessive cause of colorectal cancer (CRC), medulloblastoma (MDB), and ovarian cancer. Nevertheless, little is known about its function in lung cancers. Methods: We first knocked down β-catenin by siRNA to investigate its effects on lung cancer cell proliferation, migration and apoptosis. Then we verified the interaction between β-catenin and CREB binding protein (CBP) by immunofluoresence and co-immunoprecipition assays. Finally, the expression of β-catenin and CBP in human lung adenocarcinoma specimens were analyzed by immunohistochemistry assay. Results: β-catenin knockdown inhibited cell proliferation, promoted apoptosis and suppressed cell migration in A549 and H460 cells accompanied by the decreased expression of Myc, PCNA, VEGF, CD44, MMP-9, MMP-13 and activated bax/caspase-3 pathway. Furthermore, co-immunoprecipition and immunofluoresence analyses revealed that CBP interacted with β-catenin and contributed to β-catenin-mediated lung cancer cell growth. Abolishment of their interaction by the Wnt/ β-catenin inhibitor ICG-001 remarkably suppressed cell proliferation. Immunohistochemistry assay of tissue microarrays from patients with lung cancer indicated that both CBP and β-catenin were highly expressed in tumor tissues and predicted poor prognosis in lung adenocarcinoma patients. Conclusions: Our study has provided new evidence for the role of β-catenin in promoting the growth of lung cancer cells through cooperation with CBP, and suggested that dual targeting of β-catenin and CBP could be a potential therapeutic strategy in lung cancer treatment.
Introduction
As the most common cancer type all over the world, lung cancer has very high incidences of recurrence, metastasis and mortality [1] [2] [3] . Despite the rapid development in clinical therapeutic strategies, the five-year survival rate for lung cancer is still lower than 20% [4] . Therefore, there is an urgent need to clarify the underlying precise mechanisms that drive lung carcinogenesis and development to provide insights into the discovery of novel therapeutic targets.
β-catenin, an integral structural component of cell adhesion junctions, is the key effector of canonical Wnt signaling in the nucleus [5] . It is mainly composed of three domains: the N-terminal domain (NTD), the central region with residues 141-664 that form 12 imperfect Armadillo repeats, and the C-terminal domain (CTD) essential for the signaling activity of β-catenin [6] . The functional output of β-catenin can be affected by post-translational modifications including phosphorylation, ubiquitylation, acetylation and glycosylation [7] . Moreover, it is reported to regulate a set of genes involved in proliferation, cell self-renewal, survival, and differentiation through interactions with transcriptional coactivators. However, the precise function and molecular mechanisms of β-catenin in lung cancer progression remain unclear.
CREB binding protein (CBP) and P300 have been reported to be involved in cell growth, transformation and development [8] . Some studies showed that these transcriptional coactivators functioned as tumor-suppressors [9] [10] [11] , whereas some other studies demonstrated that they were essential for the actions of many oncogenes such as AP-1, c-jun and c-fos [12] [13] [14] . Whether CBP promotes apoptosis or cell proliferation appears to be context-dependent, and our study showed here that CBP expression was negatively correlated with the overall survival in lung cancer patients.
In this study, we examined the effects of β-catenin in lung cancer development by knocking down its expression in cancer cell lines. Also, we identified its interaction with CBP and their synergy in co-regulating lung cancer cell growth. Furthermore, we assessed the expression of CBP and β-catenin, their correlation and clinical significance in 80 lung adenocarcinoma patients with a median follow-up of 39 months. All the results have collectively indicated a pivotal role of the CBP/β-catenin axis in transcriptional regulation in lung cancer development, and that it may serve as a new therapeutic target in advanced lung cancer.
Materials and Methods

Cell lines and cell culture
Three lung cancer cell lines, H1299, A549 and H460, as well as human lung fibroblast cell line HLF were purchased from ATCC. HLF was cultured in DMEM medium, while H1299, A549 and H460 were cultured in RPMI1640, supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C with 5% CO 2 .
MTT assay
Cell viability was determined by MTT assay. H1299, A549 and H460 cells were seeded in 96-well plates (5000 cells per well), treated with drugs or plasmids or siRNAs. 48 h after treatment, MTT (0.1%) was added into each well, and incubated at 37°C for 4 h. Absorbance at 492 nm was then measured.
Western blot 30 µg proteins were separated by 4%-10% SDS-PAGE, transferred to 0.45 μm PVDF membranes and immunoblotted respectively with antibodies against β-catenin (CST) at 1:1000, CBP (CST) at 1:1000, c-Myc (proteintech) at 1:500, PCNA (santa cruz) at 1:500, GAPDH (proteintech) at 1:5000, Bcl-2 (proteintech) at 1:500 , Bax (proteintech) at 1:500, cleaved-caspase3 (CST) at 1:1000, MMP-9 (proteintech) at 1:1000, MMP-13 (Santa Cruz) at 1:500, CD44 (proteintech) at 1:500, VEGF (proteintech) at 1:500, N-cadherin (proteintech) at 1:1000, E-cadherin (proteintech) at 1:1000, Claudin (CST) at 1:1000, and TFaB (abcam) at 1:2000. Protein bands were detected by ECL (Thermo) according to manufacturer's protocol.
Confocal immunofluorescence
HLF, H1299, A549 and H460 cells were seeded on chamber slides in 6-well plates. The cells were fixed with 4% paraformaldehyde for 30 min at room temperature and permeabilized with PBST, then blocked with 10% BSA for 30 min and incubated with antibodies against β-catenin (diluted to 1:100 with 5% BSA, CST 8480S) and CBP (diluted to 1:100 with 5% BSA, Santa Cruz sc-7300) overnight at 4°C. After washing 3 times, cells were incubated with the fluorescein isothiocyanate and rhodamine-conjugaed secondary antibodies (diluted to 1:200 with 5% BSA, CST 4408S and 4413S) for 1 h. Then the nuclei were stained with DAPI for 5 min, washed with PBS for 5 times. The images were captured by Leica DM14000B confocal laser scanning microscope.
Co-Immunoprecipitation
The nuclear lysate was mixed with the antibodies against CBP or β-catenin and kept rotating at 4°C for 3.5 h. Then the protein A/G agarose beads were added and continuously incubated at 4°C overnight. After washing with PBS buffer, the beads were mixed with loading buffer and boiled at 100°C for 5 min. After centrifugation, the proteins in the supernatant were separated by SDS-PAGE and detected by Western blot.
Human tissue microarray
The lung adenocarcinoma tissue microarrays were purchased from Outdo Biotech Company (Shanghai, China). All of the specimens from 90 lung adenocarcinoma patients (median age: 61.5 years; range from 30 to 84 years; 41 females and 49 males) with complete surgical resection were collected between July 2004 and June 2009. Among 90 patients, 10 with no clinical stages were excluded. The rest cases were arranged into two tissue array blocks with carcinoma tissues and adjacent normal tissues. The 7th edition International Union Against Cancer/American Joint Committee on Cancer TNM classification was applied to all enrolled patients [15] . The follow-up time range from 1 to 121 months after the primary operation (median follow-up time: 39 months).
Immunohistochemical staining (IHC)
The tissue array blocks with specimens were fixed with formalin, briefly incubated with xylene, rehydrated with graded ethanol solution, incubated with methyl alcohol containing 3% hydrogen peroxide and immersed in a citrate buffer for antigen retrieval. IHC staining was performed using StreptavidinPeroxidase IHC assay kit (ZSGB-bio, China). The antibodies against β-catenin (CST, dilution 1:50) and CBP (Santa Cruze, dilution 1:200) were used. Immunostaining was evaluated by two pulmonary pathologists using a blind protocol design. For each specimen, the total score of CBP and β-catenin expression was calculated as staining intensity (negative staining: 0 point; weak staining: 1 point; moderate staining: 2 point; and strong staining: When the sample was scored ≥6 point, we defined it as high expression, and low expression otherwise. The positive control of CBP and β-catenin were set up according to lung cancer from the proteinatlas website (Http://www.proteinatlas.org).
Statistical analysis
Analysis of variance (ANOVA) and Student's t-test were used to compare the values of the test and control samples. The association between CBP and β-catenin expression and categorical variables were evaluated by Pearson chi-squared test. Survival curves were calculated by Kaplan Meier method. The logrank test was used to analyze the overall survival (OS) time between different clinicopathological factors in lung adenocarcinoma. Univariate and multivariate analyses were performed using the Cox regression model. Data were analyzed by SPSS 2.0 software. P<0.05 was considered statistically significant. All experiments were done three times, and the mean values and standard deviation were calculated.
Results
β-catenin knockdown inhibited the proliferation of lung cancer cells
In order to clarify the protential role of β-catenin in lung cancer progression, we knocked down the expression of β-catenin with its specific siRNAs in human lung cancer cell lines H1299, A549 and H460. As is shown in Fig. 1A , the proliferation of all three cell lines was inhibited by β-catenin knockdown. Moreover, western blot analysis indicated that the inhibition of cell proliferation was accompanied by the reduced expression of c-myc and PCNA in A549 and H460 cells (Fig. 1B) , suggesting the promotive effect of β-catenin in lung cancer cell proliferation. 
β-catenin knockdown induced apoptosis of lung cancer cells
We next assessed the effect of β-catenin in apoptosis by AV-PI assay. As is shown in Fig.  2A , compared to the control group, knockdown of β-catenin by siRNA-2 resulted in more apoptosis in lung cancer cells. Also, we detected some apoptosis markers by western blot and found that knockdown of β-catenin increased the expression of cleaved caspase-3 and Bax, but decreased the expression of Bcl-2 compared with the non-specific siRNA treatment group (Fig. 2B) . The results demonstrated that the anti-proliferative effect of β-catenin knockdown in lung cancer cells was partially ediated by apoptosis induction.
β-catenin knockdown inhibited lung cancer cell migration
We further investigated the effect of β-catenin knockdown on cell migration in lung cancer cells by scratch assay. The wound space was almost fully occupied after 72 h in both A549 and H460 cells transfected with control siRNA. In contrast, the wound space still existed in the group treated by β-catenin siRNA ( Fig. 3A and 3C) . Additionally, the expression of N-cadherin, claudin, CD44, VEGF, MMP-9, and MMP-13, which were usually involved in cell migration, were inhibited and E-cadherin was increased in both A549 and H460 cells transfected by β-catenin siRNA ( Fig. 3B and 3D ). These results suggested the involvement of β-catenin in the epithelial-mesenchymal transition (EMT) process of lung cancer development.
β-catenin interacted with CBP to co-regulate lung cancer cell growth
Based on the previous studies showing that CBP not only regulated lung carcinoma growth by activating multiple signaling pathways [16] , but also interacted with β-catenin as a Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry transcriptional co-activator to activate downstream target genes [17] , we deduced that they might synergize to co-regulate lung tumor growth. To test this hypothesis, immunofluoresence assay was performed. As is shown in Fig. 4A , β-catenin largely co-localized with CBP in the nuclei of lung cancer cells, though it was also distributed in cell membranes and cytoplasm. To further examine their interaction, co-IP experiment was done. The nuclear extracts from lung cancer cells and normal cells were immunoprecipitated with antibodies against CBP, β-catenin or the control IgG, respectively. Then, the immunoprecipitated proteins were detected by western blot using antibodies against β-catenin or CBP. As is shown in Fig. 4B , one of them was immunoprecipitated by the antibody of the other, indicating that they interacted physically. Next, we examined the synergistic effect of CBP and β-catenin in regulating cell proliferation. A549 and H460 cells were transfected with CBP overexpression plasmid alone or CBP overexpression plasmid and β-catenin siRNA together. 48 hours after transfection, cell viability was detected. We found that β-catenin knockdown reversed the increased cell viability caused by CBP overexpression (Fig. 4C) . Similarly, CBP knockdown or inhibition of its histone acetyltransferase (HAT) activity reversed the improved cell viability by β-catenin overexpression (Fig. 4D) . The small molecule ICG-001 has been found to disrupt the interaction between CBP and β-catenin [18] , and its therapeutic potential has recently been reported in pancreatic ductal adenocarcinoma (PDAC) [19] . Here, we evaluated the effect of ICG-001 on lung cancer growth, and found that ICG-001 significantly inhibited lung cancer cell growth in a dose-dependent manner (Fig. 4E ). In addition, the colony formation ability of lung cancer cells was also significantly decreased by ICG-001 treatment (Fig. 4F) , suggesting the key role of CBP/β-catenin interaction in promoting lung cancer growth. 
β-catenin and CBP were both highly expressed in lung cancer cells and tissues
Considering the interaction between β-catenin and CBP, we then checked the correlation of their expression in both lung cancer cells and tissues. The three lung cancer cell lines tested all had higher protein levels of β-catenin and CBP in whole cell lysates as well as nuclear lysates than normal cells (Fig. 5A and 5B). Furthermore, IHC analysis showed that both β-catenin and CBP were highly expressed in the carcinoma tissues in over 40% (33 out of 80) of the patient samples (Fig. 5C-5E ). These results indicated that β-catenin and CBP were highly expressed in lung cancer and their expression was positively correlated.
The clinical significance of β-catenin/CBP expression in lung cancer
The IHC staining of β-catenin and CBP in 80 lung adenocarcinoma patient samples with different clinical stages (stage I (n=32), stage II (n=18), and stage III (n=30)) demonstrated that patients in more advanced stage had higher levels of β-catenin and CBP expression ( Fig. 6A and 6B) . Furthermore, the analysis of the clinicopathological significance showed that the expression of CBP was highly associated with lung tumor differentiation (P=0.031), whereas the expression of β-catenin was associated with regional lymph node involvement (pN) (p=0.045) (Fig. 6C) .
Univariate analysis revealed that the overall survival (OS) rate of patients with lower CBP expression was significantly higher than the patients with higher CBP expression (P=0.045) (Fig. 6D and Table 1 ; the 5-year OS rate: 51.7% vs 29.3%). However, the OS was not significantly different between patients with high and low β-catenin expression (P=0.666) (Fig. 6E and Table 1 ). Moreover, multivariate survival analysis revealed that high CBP expression was a significant hazard ratio (HR) predictor for lung adenocarcinoma (HR=2.135, 95% CI: 1.154-3.952, P=0.016) ( Table 2) . Discussion β-catenin is short-lived in normal states [20] , and its stability is regulated by Wntdependent pathway. Once it is phosphorylated by GSK3β [21] , it is ubiquitinated for subsequent degradation by the 26S proteasome [22] . Recent studies have demonstrated that the stability of β-catenin can be affected by Wnt-independent mechanisms. For instance, Siah-1 can enhance the binding activity of Ebi to β-catenin, which subsequently promotes the degradation of β-catenin [23, 24] . In pathological conditions, β-catenin may escape from its degradation fate by mutations that prevent it from being phosphorylated by GSK3β [25, 26] . In our study, we found that β-catenin was overexpressed in lung cancer cells, and its knockdown led to lung cancer cell growth inhibition and apoptosis induction. It deserves further investigation whether the aberrant expression of β-catenin was due to the mutations of its phosphorylate sites or its impaired degradation.
Some studies have shown that β-catenin can be acetylated by CBP at lysine 49, but the unacetylatable form of β-catenin is an activator of the c-Myc gene, which suggest that acetylation of β-catenin by CBP may act negatively to regulate transcription [27] . In contrast, there are also instances showing that CBP acts positively to co-activate β-catenin-dependent transcription, and its acetyltransferase activity is not necessary for such activation [28, 29] . To untangle the relationship between β-catenin and CBP in lung cancer cells, we found that CBP and β-catenin interacted with each other, and the regulation of lung cancer cell growth mediated by β-catenin was CBP-dependent. It remains to be elucidated whether CBP acetylates β-catenin in lung cancer cells, and if so, whether such acetylation has oncogenic or tumor suppressive effect. As a specific inhibitor of β-catenin/CBP interaction, ICG-001 represses a subset of β-catenin-mediated transcription. In this study, ICG-001 was used to treat lung cancer cells to see whether disruption of β-catenin/ CBP interaction inhibited lung tumor growth. Similar to the effects of β-catenin knockdown, ICG-001 also caused significant growth suppression of lung cancer cells, which was consistent with with its reported function in Pancreateic cancer cells [18] . The IC 50 values of ICG-001 for H1299,A549 and H460 are 45.8μM,41.4μM and 39.4μM respectively，which were similar to the study in hepatpcellular carcinoma cell lines [30] . Furthermore, ICG-001 regulated many genes altered by β-catenin knockdown, including MMP 9 and c-Myc. All these results supported that the promotion of lung tumor progression mediated by β-catenin was CBP-dependent, and the disruption of β-catenin/CBP might be a new option in targeting therapy of lung cancer.
Accumulating evidence has strongly suggested that β-catenin is a crucial factor in various processes of cancer development [31] [32] [33] [34] [35] . In our study, we found that β-catenin expression was associated with regional lymph node involvement but not the overall survival. Taking into account the previous studies demonstrating that β-catenin was locaized in both the cytoplasm and the nucleus [36] , we speculate here that the clinical function of β-catenin is, at least in part, determined by its subcellular localization. This will be addressed in future studies with larger sample cohorts.
Conclusion
In summary, our study has revealed the high expression of β-catenin in lung cancer cells and its role in lung tumorigenesis. Notably, we uncovered its interaction with CBP, and their synergy in lung cancer development. Our research has suggested a new therapeutic strategy for lung cancer treatment by targeting the β-catenin/CBP signaling axis. 
